8/1010 sources · 7 publishersUpdated Nov 4, 16:35 UTC
Zimmer Biomet posts Q3 2026 results and lifts full‑year outlook
Zimmer Biomet reported third‑quarter 2026 net sales of $2.063 billion, up 3.1% year‑over‑year, while diluted earnings per share fell to $1.00, a 13.8% decline. Adjusted EPS was $1.90, matching the prior year. The company raised its full‑year 2026 adjusted EPS guidance to $8.50‑$8.60 and increased its revenue growth outlook.
Why it matters
The higher guidance signals management’s confidence in continued franchise growth and may support the stock’s recent price gains (the company’s shares rose about 9% after the release). The raised EPS range gives investors a new target for earnings performance this year.
Key facts
- 1Third‑quarter net sales were $2.063 billion, a 3.1% increase on a reported basis. prnewswire.com
- 2Net sales grew 3.7% on a constant‑currency basis. prnewswire.com
- 3Diluted earnings per share were $1.00, down 13.8% from the prior year. prnewswire.com
- 4Adjusted diluted earnings per share were $1.90, unchanged from the prior year. prnewswire.com
- 5Full‑year 2026 adjusted EPS guidance was updated to $8.50‑$8.60. prnewswire.com
- 6Management also indicated a revenue growth outlook of 3.0%‑3.5% for the full year. prnewswire.com
Open questions
- Some outlets cite a higher full‑year revenue growth outlook of 4.4%‑4.9%, which conflicts with the 3.0%‑3.5% range reported in the primary press release.
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.